Cambridge Cognition Holdings PLC Change of Auditor (1928U)

TIDMCOG

RNS Number : 1928U

Cambridge Cognition Holdings PLC

22 November 2023

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Change of Auditor

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, announces that the Board has approved the appointment of Crowe UK LLP ("Crowe") as the Group's new external auditor following a competitive audit tender process, and that Grant Thornton UK LLP ("Grant Thornton") has resigned as the Group's auditor.

Crowe will conduct the audit of the Group's financial statements for the financial period to 31 December 2023 and a proposal to re-appoint Crowe as auditors of the Group will be subject to the approval of shareholders at the 2024 Annual General Meeting.

Grant Thornton has been the auditor for the Company since 2013 and we thank them for their services over this time. Grant Thornton has confirmed to the Company that there are no matters connected with their ceasing to hold office that need to be brought to the attention of the members or creditors of the Company for the purposes of section 519 of the Companies Act 2006.

Enquiries

 
Cambridge Cognition Holdings Plc              Tel: [phone] 
 Matthew Stork, Chief Executive Officer        [e-mail] 
 Stephen Symonds, Chief Financial Officer 
Panmure Gordon (UK) Limited (NOMAD and Joint  Tel: [phone] 
 Broker)                                       (Corporate Finance) 
 Freddy Crossley / Emma Earl                   (Corporate Broking) 
 Rupert Dearden 
Dowgate Capital Limited (Joint Broker)        Tel: [phone] 
 David Poutney / James Serjeant 
IFC Advisory Ltd (Financial PR and IR)        Tel: [phone] 
 Tim Metcalfe / Graham Herring / Zach Cohen 
 

Notes to editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPBRBDBDBDDGXB

(END) Dow Jones Newswires

November 22, 2023 02:00 ET (07:00 GMT)